Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer

Fig. 3

Genetic alteration of MAPK8IP2 in PCa (cBioPortal). A OncoPrint visual summary of MAPK8IP2 alteration. B Schematic representation of MAPK8IP2 mutations. C Summary of MAPK8IP2 alterations in PCa from the MCTP, Nature 2012; SU2C/PCF Dream Team, PNAS 2019; and TCGA, PanCancer Atlas. D-F Kaplan–Meier plotter was used to compare the DSS (D), OS (E) and PFS (F) of patients in the MAPK8IP2 altered and unaltered groups. G, H The gene mutations of TP53 (G) and CDK12 (H) alter MAPK8IP2 expression levels. DSS: disease-specific survival; OS: overall survival; PFS: progression-free survival

Back to article page